Ocugen and Roots Pharmaceutical Complete OCU400 License Agreement for MENA
The companies completed a license agreement for OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa.
Story updates
10:32:22 AM UTC
SquawkNews
MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) NASDAQ:OCGN, a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow Inter…
10:32:55 AM UTC
SquawkNews
Ocugen signed an exclusive OCU400 license with Roots Pharmaceutical for MENA, with up to $4M initial milestones, up to $255M in sales milestones, and 22% royalties; Ocugen will supply product. Phase 3 topline readout is expected in Q1 2027.Material DetailsContext by AI AnalystThis is a strategic re…